The FDA has approved a new 100mg/mL formulation of Ultomiris® (ravulizumab-cwvz; Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and pediatric patients.
Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.
American Academy of Pediatrics policy statement updated recommendations are presented relating to use of barrier methods for adolescents engaging in sexual activity.
Tolvaptan improves the urinary lithogenic risk profile of patients with autosomal dominant polycystic kidney disease, according to researchers.
Agency now says risk among adults increases steadily with age, and is not limited to those over 65.
And, serum urate lowering with allopurinol did not affect GFR in T1DM and diabetic kidney disease.
Patients on hemodialysis who use opioids concurrently with a short-acting benzodiazepine are especially at risk for early death, a study found.
SARS-CoV-2 present in 26.7% at acute stage of infection, 8.7% of recovering patients.
Data from 3 countries showed drop in serious renal events with sodium-glucose cotransporter 2 inhibitors.
